articleThe LancetNov 1, 2019BRONZE OA

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

BBBarbara BurtnessKJKevin J. HarringtonRGRichard GreilDSDenis SoulièresMTMakoto Tahara

Yale Cancer Center · Royal Marsden NHS Foundation Trust · +21 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

3,165
total citations
FWCI
220.63
Percentile
100%
References
27
Citations per year

Authors

219

Topics & keywords

Topics
Keywords
  • Cetuximab
  • Pembrolizumab
  • Medicine
  • Chemotherapy
  • Head and neck
  • Oncology
  • Open label
  • Internal medicine
No related works found for this paper.

Funding